Circulating eosinophils associated with responsiveness to COVID-19 vaccine and the disease severity in patients with SARS-CoV-2 omicron variant infection
© 2023. The Author(s)..
OBJECTIVE: This study aimed to investigate the longitudinal circulating eosinophil (EOS) data impacted by the COVID-19 vaccine, the predictive role of circulating EOS in the disease severity, and its association with T cell immunity in patients with SARS-CoV-2 Omicron BA.2 variant infection in Shanghai, China.
METHODS: We collected a cohort of 1,157 patients infected with SARS-CoV-2 Omicron/BA.2 variant in Shanghai, China. These patients were diagnosed or admitted between Feb 20, 2022, and May 10, 2022, and were classified as asymptomatic (n = 705), mild (n = 286) and severe (n = 166) groups. We compiled and analyzed data of patients' clinical demographic characteristics, laboratory findings, and clinical outcomes.
RESULTS: COVID-19 vaccine reduced the incidence of severe cases. Severe patients were shown to have declined peripheral blood EOS. Both the 2 doses and 3 doses of inactivated COVID-19 vaccines promoted the circulating EOS levels. In particular, the 3rd booster shot of inactivated COVID-19 vaccine was shown to have a sustained promoting effect on circulating EOS. Univariate analysis showed that there was a significant difference in age, underlying comorbidities, EOS, lymphocytes, CRP, CD4, and CD8 T cell counts between the mild and the severe patients. Multivariate logistic regression analysis and ROC curve analysis indicate that circulating EOS (AUC = 0.828, p = 0.025), the combination of EOS and CD4 T cell (AUC = 0.920, p = 0.017) can predict the risk of disease severity in patients with SARS-CoV-2 Omicron BA.2 variant infection.
CONCLUSIONS: COVID-19 vaccine promotes circulating EOS and reduces the risk of severe illness, and particularly the 3rd booster dose of COVID-19 vaccine sustainedly promotes EOS. Circulating EOS, along with T cell immunity, may have a predictive value for the disease severity in SARS-CoV-2 Omicron infected patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC pulmonary medicine - 23(2023), 1 vom: 22. Mai, Seite 177 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhu, Zhuxian [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 Vaccines |
---|
Anmerkungen: |
Date Completed 24.05.2023 Date Revised 24.05.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12890-023-02473-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM357204409 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM357204409 | ||
003 | DE-627 | ||
005 | 20231226072101.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12890-023-02473-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1190.xml |
035 | |a (DE-627)NLM357204409 | ||
035 | |a (NLM)37217986 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhu, Zhuxian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Circulating eosinophils associated with responsiveness to COVID-19 vaccine and the disease severity in patients with SARS-CoV-2 omicron variant infection |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.05.2023 | ||
500 | |a Date Revised 24.05.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a OBJECTIVE: This study aimed to investigate the longitudinal circulating eosinophil (EOS) data impacted by the COVID-19 vaccine, the predictive role of circulating EOS in the disease severity, and its association with T cell immunity in patients with SARS-CoV-2 Omicron BA.2 variant infection in Shanghai, China | ||
520 | |a METHODS: We collected a cohort of 1,157 patients infected with SARS-CoV-2 Omicron/BA.2 variant in Shanghai, China. These patients were diagnosed or admitted between Feb 20, 2022, and May 10, 2022, and were classified as asymptomatic (n = 705), mild (n = 286) and severe (n = 166) groups. We compiled and analyzed data of patients' clinical demographic characteristics, laboratory findings, and clinical outcomes | ||
520 | |a RESULTS: COVID-19 vaccine reduced the incidence of severe cases. Severe patients were shown to have declined peripheral blood EOS. Both the 2 doses and 3 doses of inactivated COVID-19 vaccines promoted the circulating EOS levels. In particular, the 3rd booster shot of inactivated COVID-19 vaccine was shown to have a sustained promoting effect on circulating EOS. Univariate analysis showed that there was a significant difference in age, underlying comorbidities, EOS, lymphocytes, CRP, CD4, and CD8 T cell counts between the mild and the severe patients. Multivariate logistic regression analysis and ROC curve analysis indicate that circulating EOS (AUC = 0.828, p = 0.025), the combination of EOS and CD4 T cell (AUC = 0.920, p = 0.017) can predict the risk of disease severity in patients with SARS-CoV-2 Omicron BA.2 variant infection | ||
520 | |a CONCLUSIONS: COVID-19 vaccine promotes circulating EOS and reduces the risk of severe illness, and particularly the 3rd booster dose of COVID-19 vaccine sustainedly promotes EOS. Circulating EOS, along with T cell immunity, may have a predictive value for the disease severity in SARS-CoV-2 Omicron infected patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 vaccine | |
650 | 4 | |a Disease severity | |
650 | 4 | |a Eosinophil (EOS) | |
650 | 4 | |a Omicron variant | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a T cell immunity | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
700 | 1 | |a Cai, Jixu |e verfasserin |4 aut | |
700 | 1 | |a Tang, Qiang |e verfasserin |4 aut | |
700 | 1 | |a Mo, Yin-Yuan |e verfasserin |4 aut | |
700 | 1 | |a Deng, Tiantian |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Xiaoyu |e verfasserin |4 aut | |
700 | 1 | |a Xu, Ke |e verfasserin |4 aut | |
700 | 1 | |a Wu, Beishou |e verfasserin |4 aut | |
700 | 1 | |a Tang, Haicheng |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Ziqiang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d 2001 |g 23(2023), 1 vom: 22. Mai, Seite 177 |w (DE-627)NLM114960313 |x 1471-2466 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:22 |g month:05 |g pages:177 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12890-023-02473-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 22 |c 05 |h 177 |